림프종 환자에서 리툭시맙 치료 후에 발생한 저감마글로불린혈증 = A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma

다국어 초록 (Multilingual Abstract)

Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin`s lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review. (Korean J Med 2014;87:357-362)

참고문헌 (Reference)

1 Capolunghi F, "Why do we need IgM memory B cells" 152 : 114-120, 2013

2 Hicks LK, "Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma" 43 : 701-708, 2009

3 Walewski J, "Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study" 18 : 141-148, 2001

4 Walker AR, "Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma" 26 : 431-433, 2008

5 Casulo C, "Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections" 13 : 106-111, 2013

6 Kurokawa T, "Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab" 29 : 5-9, 2011

7 Nishio M, "FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation" 82 : 143-147, 2009

8 Abulayha AM, "Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma" 34 : 307-311, 2010

9 Avanzini MA, "B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells" 33 : 480-486, 2005

10 Anolik JH, "B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny" 122 : 139-145, 2007